ADCdb / ADC Review
ADCdb and ADC Review are where to track the hundreds of ADCs in trials, with target, payload, and linker.
ADCdb (academic) structures >6,000 ADC records; ADC Review covers conference data (AACR, ASCO, ESMO).
Pages like this
not linked directly; found by shared links- IdeaUse SLFN11 status to decide which antibody-drug payload to give next
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- Key paperPOLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- IdeaCheck whether a tumour can still show itself to the immune system
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- IdeaTROP2 PET to choose and sequence TROP2 ADCs
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- TechnologyTROP2 PET
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- Key paperTROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- Key paperDESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).
- Key paperDESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group
Shares Biomarkers are not validated or standardised, Antibody-drug conjugate (ADC).